WaveMan
WaveMan · Company
HOWL · Werewolf Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

HOWL Werewolf Therapeutics (HOWL) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001785530
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
19
13F, latest reported quarter

What the filings say about HOWL

Insiders, 180 days
-$2.0M net sold
3 sellers · 0% of sales under a 10b5-1 plan

Werewolf Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Werewolf Therapeutics, Inc. insiders sold a net $2.0M of stock across 172 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
EVNIN LUKE
Director
SELL
2026-07-08 SECtraded 2026-07-07
107,429
$33.3K
+158.6%
Context
  • 87 earlier Form 4 trades (code P or S) here by this insider (87 sales), the last on Jul 6, 2026.
  • 2 other insiders sold within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director EVNIN LUKE sold about $33.3K of HOWL on Jul 7, 2026; 2 other insiders sold within 30 days and 19 funds added in the latest 13F quarter.
EVNIN LUKE
Director
SELL
2026-07-08 SECtraded 2026-07-06
35,770
$11.4K
+158.6%
Context
  • 86 earlier Form 4 trades (code P or S) here by this insider (86 sales), the last on Jun 29, 2026.
  • The trade is 33.3% of the 107,429 shares held after it.
  • 2 other insiders sold within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director EVNIN LUKE sold about $11.4K of HOWL on Jul 6, 2026; 2 other insiders sold within 30 days and 19 funds added in the latest 13F quarter.
EVNIN LUKE
Director
SELL
2026-06-29 SEC
157,084
$47.1K
+172.2%
Context
  • 85 earlier Form 4 trades (code P or S) here by this insider (85 sales), the last on Jun 9, 2026.
  • The trade is 109.7% of the 143,199 shares held after it.
  • 2 other insiders sold within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director EVNIN LUKE sold about $47.1K of HOWL on Jun 29, 2026; 2 other insiders sold within 30 days and 19 funds added in the latest 13F quarter.
RA CAPITAL MANAGEMENT, L.P.
SELL
2026-06-22 SECtraded 2026-06-17
389,216
$136.2K
+170.7%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Jun 16, 2026.
  • The trade is 9.1% of the 4,268,448 shares held after it.
  • 2 other insiders sold within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider RA CAPITAL MANAGEMENT, L.P. sold about $136.2K of HOWL on Jun 17, 2026; 2 other insiders sold within 30 days and 19 funds added in the latest 13F quarter.
RA CAPITAL MANAGEMENT, L.P.
SELL
2026-06-22 SECtraded 2026-06-17
27,695
$9.7K
+170.7%
Context
  • 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Jun 16, 2026.
  • The trade is 9.1% of the 303,719 shares held after it.
  • 2 other insiders sold within 30 days.
  • 19 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider RA CAPITAL MANAGEMENT, L.P. sold about $9.7K of HOWL on Jun 17, 2026; 2 other insiders sold within 30 days and 19 funds added in the latest 13F quarter.
172 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 167 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$2.0M over 180 days
-$963.9K of it by a 10%+ holder
below 70% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
19 funds bought in last quarter
below 70% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
5.5% of the float short (float per yahoo 2026-10-26) · 3.7 days to cover · settled 2026-09-30
more than 52% of Pharma & Biotech
What changed in the last 30 days
Oct 27Insider selling stopped: no sales in 90 days after 48 in the prior 90
Why it matters
The absence is the signal: 48 sales in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch HOWL

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-38.4%12M
-81%-50%-19%+11%2025-102025-122026-022026-042026-062026-082026-10 2026-05-08 · RA CAPITAL MANAGEMENT, L.P. sold $249.6K2026-05-08 · EVNIN LUKE sold $214.0K2025-10-29 · MPM BioVentures 2014 LLC sold $208.1K2025-10-29 · UBS Oncology Impact Fund L.P. sold $208.1K2025-11-04 · MPM BioVentures 2014 LLC sold $171.4K2025-11-04 · MPM BioImpact LLC sold $171.4K2025-10-31 · MPM Asset Management Investors BV2014 LLC sold $146.0K2025-10-31 · MPM ONCOLOGY INNOVATIONS FUND LP sold $146.0K2026-06-17 · RA CAPITAL MANAGEMENT, L.P. sold $136.2K2025-10-29 · EVNIN LUKE sold $133.5K2026-06-09 · Kolchinsky Peter sold $127.7K2025-10-27 · MPM BioVentures 2014 LLC sold $125.1K2025-10-27 · UBS Oncology Impact Fund L.P. sold $125.1K2025-10-30 · MPM Asset Management Investors BV2014 LLC sold $124.3K2025-10-30 · MPM ONCOLOGY INNOVATIONS FUND LP sold $124.3K2025-11-03 · MPM Asset Management Investors BV2014 LLC sold $121.3K2025-11-03 · MPM ONCOLOGY INNOVATIONS FUND LP sold $121.3K2026-04-30 · EVNIN LUKE sold $121.1K2025-10-28 · MPM BioVentures 2014 LLC sold $113.3K2025-10-28 · UBS Oncology Impact Fund L.P. sold $113.3K2025-11-04 · EVNIN LUKE sold $110.0K2025-10-31 · EVNIN LUKE sold $93.7K2026-06-11 · Kolchinsky Peter sold $93.1K2025-11-13 · MPM BioVentures 2014 LLC sold $89.1K2025-11-13 · MPM Oncology Innovations Fund GP LLC sold $89.1K2025-11-24 · MPM BioVentures 2014 GP LLC sold $87.0K2025-11-24 · MPM Oncology Innovations Fund GP LLC sold $87.0K2025-12-04 · MPM BioVentures 2014 (B), L.P. sold $80.7K2025-12-04 · MPM BioImpact LLC sold $80.7K2025-10-27 · EVNIN LUKE sold $80.3K2025-10-30 · EVNIN LUKE sold $79.8K2025-11-03 · EVNIN LUKE sold $77.9K2025-11-07 · MPM BioVentures 2014, L.P. sold $76.0K2025-11-07 · UBS Oncology Impact Fund L.P. sold $76.0K2025-10-28 · EVNIN LUKE sold $72.7K2026-04-28 · EVNIN LUKE sold $69.7K2025-12-29 · EVNIN LUKE sold $66.2K2025-11-06 · MPM BioVentures 2014 LLC sold $65.9K2025-11-06 · MPM BioImpact LLC sold $65.9K2026-06-12 · RA CAPITAL MANAGEMENT, L.P. sold $63.6K2025-11-11 · MPM BioVentures 2014, L.P. sold $63.6K2025-11-11 · UBS Oncology Impact Fund L.P. sold $63.6K2026-07-06 · MPM Asset Management LLC filed to sell $5.2K2026-07-06 · MPM Asset Management Investors BV2014 LLC filed to sell $1.1K2026-07-06 · MPM BioVentures 2014 (B), L.P. filed to sell $2.2K2026-07-06 · MPM BioVentures 2014, L.P. filed to sell $33.0K2026-07-06 · MPM Oncology Innovations Fund, L.P. filed to sell $7.2K2026-07-06 · UBS Oncology Impact Fund, L.P. filed to sell $27.3K2026-06-29 · MPM Asset Management LLC filed to sell $5.4K2026-06-29 · MPM Asset Management Investors BV2014 LLC filed to sell $1.2K2026-06-29 · MPM BioVentures 2014 (B), L.P. filed to sell $2.3K2026-06-29 · MPM BioVentures 2014, L.P. filed to sell $34.3K2026-06-29 · MPM Oncology Innovations Fund, L.P. filed to sell $7.5K2026-06-29 · UBS Oncology Impact Fund, L.P. filed to sell $28.4K
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns HOWL: institutional holders (13F)

13F holdings, latest reported quarter
RA CAPITAL MANAGEMENT, L.P.
2,387,744 sh
$859.3K
Balyasny Asset Management L.P.
1,790,089 sh
$644.3K
Lynx1 Capital Management LP
1,315,572 sh
$473.5K
VANGUARD CAPITAL MANAGEMENT LLC
1,217,976 sh
$438.5K
RENAISSANCE TECHNOLOGIES LLC
674,632 sh
$242.8K

Congress trades in HOWL

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

HOWL planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
MPM Asset Management LLC
Filed 2026-07-06
$5.2K
MPM Asset Management Investors BV2014 LLC
Filed 2026-07-06
$1.1K
MPM BioVentures 2014 (B), L.P.
Filed 2026-07-06
$2.2K
MPM BioVentures 2014, L.P.
Filed 2026-07-06
$33.0K
MPM Oncology Innovations Fund, L.P.
Filed 2026-07-06
$7.2K

HOWL mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$96.6K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$123.9K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$10.5K position · as of 2026-05-31
0.0%
Fidelity Total Market Index Fund
$24.6K position · as of 2026-05-31
0.0%
Fidelity Series Total Market Index Fund
$19.2K position · as of 2026-05-31
0.0%
VANGUARD TOTAL STOCK MARKET INDEX FUND
$314.5K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
0 active
1
Multi-phase
0 active
What changed recently
A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients Wit
2026-10-20 · Active Not Recruiting → Completed
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $2.0M sold by insiders over 180 days, 19 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

HOWL financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$30.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
1.97x
long-term debt only, 2026-03-31; equity 2026-06-30
Cash flow to debt
-0.94x
TTM operating cash flow over long-term debt only, 2026-03-31
Return on equity
-119.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-59.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-66.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$57.7M
market value at close 2026-10-23 on 2026-07-27 shares, plus long-term debt only, 2026-03-31, minus cash 2026-06-30
FCF yield
-63.3%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$60.7M-$73.6M-$40.5M-$56.1M
Net income-$60.8M-$70.5M-$37.4M-$53.8M
EPS (diluted)-1.33-1.63-1.05-1.86
Operating cash flow-$60.3M-$56.2M-$32.6M-$40.6M
Cash$57.0M$111.0M$134.3M$129.3M
Long-term debt$32.1M$32.1M$40.0Mn/a
SEC XBRL, fiscal years, as known on 2026-10-27

HOWL Stock Sonar score 5/7 axes

Find similar shapesCompare

HOWL ranks highest on risk and compliance (56th percentile) and profitability (35th), and lowest on insider conviction (15th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
35
Inputs
  • Return on equity-119.9% · 28 pct, sector of 545
  • Return on assets-59.3% · 38 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-66.7% · 38 pct, sector of 576
Financial health
32
Inputs
  • Debt to equity1.97x · 10 pct, sector of 352
  • Cash flow to debt-0.94x · 54 pct, sector of 371
Insider conviction
15
Inputs
  • Net Form 4 buying (codes P and S), 180d-$2.0M · 29 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
30
Inputs
  • Funds adding, latest quarter19 · 30 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
56
Inputs
  • Short interest, % of float+5.5% · 56 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

HOWL filings, in plain words

Are Werewolf Therapeutics insiders buying or selling HOWL?

In the 180 days to 2026-10-27, Werewolf Therapeutics insiders were net sellers, a net $2.0M across purchases and sales reported on Form 4, by 3 sellers.

Read the full summary

In the 180 days to 2026-10-27, Werewolf Therapeutics insiders were net sellers of HOWL, a net $2.0M across purchases and sales reported on Form 4 by 3 sellers. None of the 49 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies